Lykos Therapeutics has announced significant staff reductions following the U.S. Food and Drug Administration’s (FDA) rejection of their application for the use of MDMA capsules in treating post-traumatic stress disorder (PTSD) in adults. This decision marks a pivotal moment for the biotech company, necessitating a strategic shift as they work to address the FDA’s concerns and continue their pursuit of regulatory approval.
FDA’s Rejection and Its Implications
The FDA’s decision to reject the MDMA treatment was delivered after the Psychopharmacologic Drugs Advisory Committee voted against its approval. The committee’s decision required Lykos to conduct an additional Phase 3 trial to further evaluate the safety and efficacy of the MDMA capsules. This unexpected outcome has prompted Lykos to reorganise its operations and focus on meeting the FDA’s requirements.
In response to the FDA’s decision, Lykos announced a reorganisation that includes cutting 75% of its workforce. The remaining employees will concentrate on clinical development, medical affairs, and ongoing engagement with the FDA. The company aims to efficiently navigate the regulatory landscape while maintaining its commitment to advancing MDMA as a treatment for PTSD.
Strategic Appointments and Future Directions
As part of their strategic adjustments, Lykos appointed Dr. David Hough, a former Janssen executive, as senior medical advisor. Dr. Hough will oversee clinical development and regulatory interactions, focusing on addressing the FDA’s concerns for resubmission. His expertise is expected to enhance Lykos’ ability to constructively engage with the FDA and ensure rigorous clinical evaluations.
In addition, Lykos has established an independent advisory board to provide guidance and support throughout the resubmission process. This move emphasises the company’s dedication to refining its clinical strategy and aligning with regulatory expectations.
Retraction of Research Papers
The FDA’s rejection coincides with the retraction of three research papers on MDMA-assisted psychotherapy by the journal Psychopharmacology. The journal cited data integrity issues and protocol violations at a study site associated with the projects. These retractions underscore the importance of transparency and adherence to ethical standards in clinical research, both of which are pivotal for Lykos as they move forward.
The Wall Street Journal’s recent exposé on Lykos’ clinical trials reported that some patients felt pressured to report positive outcomes, while others experienced intensified trauma-related memories. These revelations highlight the complexities of MDMA-assisted therapy and the challenges faced in ensuring patient safety and accurate data collection.
Leave a Reply